Clearbridge Investments LLC Has $387.34 Million Stock Holdings in argenx SE (NASDAQ:ARGX)

Clearbridge Investments LLC lifted its holdings in shares of argenx SE (NASDAQ:ARGX) by 6.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 629,828 shares of the company’s stock after purchasing an additional 40,330 shares during the quarter. Clearbridge Investments LLC owned approximately 1.04% of argenx worth $387,344,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Steward Partners Investment Advisory LLC lifted its position in shares of argenx by 5.6% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company’s stock worth $234,000 after buying an additional 20 shares during the last quarter. SG Americas Securities LLC lifted its holdings in argenx by 6.2% in the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock worth $220,000 after purchasing an additional 21 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in argenx by 38.2% during the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock valued at $47,000 after purchasing an additional 21 shares during the last quarter. Dynasty Wealth Management LLC raised its position in shares of argenx by 3.4% in the fourth quarter. Dynasty Wealth Management LLC now owns 677 shares of the company’s stock valued at $416,000 after purchasing an additional 22 shares during the period. Finally, Choreo LLC lifted its stake in shares of argenx by 4.4% in the fourth quarter. Choreo LLC now owns 551 shares of the company’s stock worth $342,000 after buying an additional 23 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

argenx Trading Down 0.7 %

Shares of NASDAQ ARGX opened at $589.15 on Friday. argenx SE has a 1-year low of $352.77 and a 1-year high of $678.21. The company has a 50-day moving average of $628.26 and a two-hundred day moving average of $601.66. The company has a market cap of $35.80 billion, a PE ratio of -669.49 and a beta of 0.59.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. As a group, equities research analysts forecast that argenx SE will post 3.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ARGX. Oppenheimer raised their price target on argenx from $675.00 to $704.00 and gave the company an “outperform” rating in a research report on Friday, February 28th. Sanford C. Bernstein upgraded shares of argenx from a “market perform” rating to an “outperform” rating in a research note on Monday, March 17th. Guggenheim upped their target price on shares of argenx from $775.00 to $1,100.00 and gave the company a “buy” rating in a research note on Monday, March 10th. Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a “sell” rating to a “hold” rating in a research report on Wednesday, March 12th. Finally, Robert W. Baird increased their target price on shares of argenx from $650.00 to $680.00 and gave the company a “neutral” rating in a research note on Tuesday, March 4th. Three investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $687.00.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.